title: [Effects of BCG-PSN on serum levels of IL-4 and IL-12 in patients with condyloma acuminatum].
abstract: OBJECTIVE
  To determine the effects of polysaccharide nucleic acid fraction of bacillus calmette guerin (BCG-PSN) on serum levels of interleukin-4 (IL-4) and interleukin-12 (IL-12) in patients with condyloma acuminatum (CA) and to investigate the mechamism of immunoregulation of BCG-PSN on CA.
  
  
  METHODS
  Sixty CA cases were randomly divided into 2 groups. The serum levels of IL-4 and IL-12 were respectively measured by Double-antibody sandwich ELISA method before and after the treatment. The serum levels of IL-12 and IL-4 of health control were also measured. The recurrent rate of each group was used as an index to assess the effect of BCG-PSN in CA patients.
  
  
  RESULTS
  Compared with healthy controls, the serum levels of IL-12 in patients with CA were decreased significantly (P < 0.05), while the serum levels of IL-4 were increased significantly (P < 0.05) before the treatment. The serum levels of IL-12 were negatively correlated with the serum levels of IL-4 (r = -0.287, P < 0.05). After the treatment, the serum levels of IL-12 were increased significantly( P < 0.05), and the serum levels of IL4 were decreased significantly (P < 0.05) in the treatment group. But in the control group, the serum levels of IL-12 and IL-4 were similar before and after the treatment (P > 0.05). The recurrent rate of treatment group was significantly lower than that of the control group (chi2 = 4.356, P < 0.05).
  
  
  CONCLUSIONS
  There is an imbalance of Th1/Th2 cytokines production in patients with condyloma acuminatum. BCG-PSN could increase the serum level of IL-12 and decrease the serum level of IL-4 in CA patients. BCG-PSN could decrease the recurrent rate of CA. The effect may be related to the regulation and modulation of BCG-PSN to Thl/Th2 cytokines imbalance,which then enhances the cellular immunity in CA patients.
authors.affiliation: Department of Dermatology and STD, Third Xiangya Hospital, Central South University, Changsha 410013, China.
authors.forename: Cheng-xin
authors.initials: CX
authors.lastname: Zuo
authors.forename: Jin-hua
authors.initials: JH
authors.lastname: Huang
authors.forename: Zhao-hui
authors.initials: ZH
authors.lastname: Liao
authors.forename: Jian-yun
authors.initials: JY
authors.lastname: Lu
authors.forename: Jing
authors.initials: J
authors.lastname: Chen
mesh_terms: D000276:Adjuvants, Immunologic / Q000737:chemistry / Q000627:therapeutic use; D000328:Adult; D001500:BCG Vaccine / Q000737:chemistry / Q000627:therapeutic use*; D003218:Condylomata Acuminata / Q000097:blood / Q000276:immunology / Q000628:therapy*; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D018664:Interleukin-12 / Q000097:blood*; D015847:Interleukin-4 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009696:Nucleic Acids / Q000302:isolation & purification / Q000627:therapeutic use; D011135:Polysaccharides, Bacterial / Q000302:isolation & purification / Q000627:therapeutic use; D055502:Secondary Prevention
chemical_list: D000276:Adjuvants, Immunologic; D001500:BCG Vaccine; D009696:Nucleic Acids; D011135:Polysaccharides, Bacterial; D018664:Interleukin-12; D015847:Interleukin-4